The genetics of alopecia areata: New approaches, new findings, new treatments

Journal of Dermatological Science

Volumn 78, Issue 1, 2015, Pages 11-20

  Biran, Roni ^a   Zlotogorski, Abraham ^a   Ramot, Yuval ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Alopecia; Alopecia areata; Genetics; GWAS; Hair; Immunology

Indexed keywords

ABATACEPT; AUTACOID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 21; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MISMATCH REPAIR PROTEIN PMS2; PEROXIREDOXIN 5; TOLL LIKE RECEPTOR 1; TUMOR NECROSIS FACTOR; GENETIC MARKER;

ALOPECIA AREATA; AUTOIMMUNITY; CLEC16A GENE; CTLA4 GENE; DISEASE ASSOCIATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; HAIR FOLLICLE; HIGH RISK PATIENT; HLA ANTIGEN GENE; HUMAN; IKZF4 GENE; IL 13 GENE; IL 2 GENE; IL 21 GENE; KIAA0350 GENE; LTA GENE; MICA GENE; MOLECULAR PATHOLOGY; NONHUMAN; PMS2 GENE; PRDX5 GENE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SPATA5 GENE; STX17 GENE; TLR1 GENE; TNF GENE; ULBP 3 GENE; ULBP 6 GENE; WHOLE GENOME SEQUENCING; ANIMAL; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; IMMUNOLOGY; PHENOTYPE; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION;

ALOPECIA AREATA; ANIMALS; AUTOIMMUNITY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHENOTYPE; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84925940937     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.01.004     Document Type: Review

References (53)

1. Safavi K.H., Muller S.A., Suman V.J., Moshell A.N., Melton L.J. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995, 70:628-633.
2. Forstbauer L.M., Brockschmidt F.F., Moskvina V., Herold C., Redler S.V., Herzog A., et al. Genome-wide pooling approach identifies SPATA5 as a new susceptibility locus for alopecia areata. Eur J Hum Genet 2012, 20:326-332.
3. Sperling L.C., Lupton G.P. Histopathology of non-scarring alopecia. J Cutan Pathol 1995, 22:97-114.
4. Petukhova L., Cabral R.M., Mackay-Wiggan J., Clynes R., Christiano A.M. The genetics of alopecia areata: what's new and how will it help our patients?. Dermatol Ther 2011, 24:326-336.
5. Ono S., Otsuka A., Yamamoto Y., Kataoka T.R., Koyanagi I., Miyachi Y., et al. Serum granulysin as a possible key marker of the activity of alopecia areata. J Dermatol Sci 2014, 73:74-79.
6. Yazdan P. Update on the genetics of androgenetic alopecia, female pattern hair loss, and alopecia areata: implications for molecular diagnostic testing. Semin Cutan Med Surg 2012, 31:258-266.
7. McDonagh A.J., Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002, 27:405-409.
8. Van der Steen P., Traupe H., Happle R., Boezeman J., Sträter R., Hamm H. The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate. Acta Derm Venereol 1992, 72:373-375.
9. McElwee K.J., Gilhar A., Tobin D.J., Ramot Y., Sundberg J.P., Nakamura M., et al. What causes alopecia areata?. Exp Dermatol 2013, 22:609-626.
10. Jackow C., Puffer N., Hordinsky M., Nelson J., Tarrand J., Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment?. J Am Acad Dermatol 1998, 38:418-425.
11. Rodriguez T.A., Fernandes K.E., Dresser K.L., Duvic M. Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol 2010, 62:525-527. National Alopecia Areata Registry.
12. Sundberg J.P., Silva K.A., Li R., Cox G.A., King L.E. Adult-onset Alopecia areata is a complex polygenic trait in the C3H/HeJ mouse model. J Invest Dermatol 2004, 123:294-297.
13. Barahmani N., Schabath M.B., Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 2009, 61:581-591. National Alopecia Areata Registry.
14. Goh C., Finkel M., Christos P.J., Sinha A.A. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol 2006, 20:1055-1060.
15. Martinez-Mir A., Zlotogorski A., Gordon D., Petukhova L., Mo J., Gilliam T.C., et al. Genomwide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007, 80:316-328.
16. Green J., Sinclair R.D. Genetics of alopecia areata. Australas J Dermatol 2000, 41:213-218.
17. Dudda-Subramanya R., Alexis A.F., Siu K., Sinha A.A. Alopecia areata: genetic complexity underlies clinical heterogeneity. Eur J Dermatol 2007, 17:367-374.
18. Du Vivier A., Munro D.D. Alopecia areata, autoimmunity, and Down's syndrome. Br Med J 1975, 1:191-192.
19. Ramot Y., Molho-Pessach V., Tenenbaum A., Zlotogorski A. Alopecia areata and Down syndrome: a true association or a coincidence. Int J Trichol 2013, 5:227-228.
20. Gilhar A., Paus R., Kalish R.S. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007, 117:2019-2027.
21. Petukhova L., Christiano A.M. The genetic architecture of alopecia areata. J Invest Dermatol Symp Proc 2013, 16:S16-S22.
22. Mapping and identifying genes conferring to complex diseases. Human molecular genetics 2004, 436-447. Taylor & Francis, New York, NY. 3rd ed. T. Strachan, A.P. Read (Eds.).
23. Kruglyak L. The road to genome-wide association studies. Nat Rev Genet 2008, 9:314-318.
24. Ito T. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol 2013, 2013:348546.
25. Shendure J., Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008, 26:1135-1145.
26. Ombrello M.J., Sikora K.A., Kastner D.L. Genetics, genomics, and their relevance to pathology and therapy. Best Pract Res Clin Rheumatol 2014, 28:175-189.
27. Ng S.B., Turner E.H., Robertson P.D., Flygare S.D., Bigham A.W., Lee C., et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009, 461:272-276.
28. Maurano M.T., Humbert R., Rynes E., Thurman R.E., Haugen E., Wang H., et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012, 337:1190-1195.
29. Lee S., Paik S.H., Kim H.J., Ryu H.H., Cha S., Jo S.J., et al. Exomic sequencing of immune-related genes reveals novel candidate variants associated with alopecia universalis. PLoS ONE 2013, 8:e53613.
30. Alzolibani A.A., Zari S., Ahmed A.A. Epidemiologic and genetic characteristics of alopecia areata (part 2). Acta Dermatovenerol Alp Pannon Adriat 2012, 21:15-19.
31. Petukhova L., Duvic M., Hordinsky M., Norris D., Price V., Shimomura Y., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-117.
32. Jagielska D., Redler S., Brockschmidt F.F., Herold C., Pasternack S.M., Garcia Bartels N., et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol 2012, 132:2192-2197.
33. Redler S., Albert F., Brockschmidt F.F., Herold C., Hanneken S., Eigelshoven S., et al. Investigation of selected cytokine genes suggests that IL2RA and the TNF/LTA locus are risk factors for severe alopecia areata. Br J Dermatol 2012, 167:1360-1365.
34. Redler S., Angisch M., Heilmann S., Wolf S., Barth S., Buket Basmanav F., et al. Immunochip-based analysis: high-density genotyping of immune-related loci sheds further light on the autoimmune genetic architecture of alopecia areata. J Invest Dermatol 2014, [Epub ahead of print]. 10.1038/jid.2014.459.
35. Ito T., Fujiyama T., Hashizume H., Tokura Y. Antihistaminic drug olopatadine down modulates T cell chemotaxis toward CXCL10 by reducing CXCR3 expression, F-actin polymerization and calcium influx in patients with alopecia areata. J Dermatol Sci 2013, 72:68-71.
36. Ito T., Hashizume H., Shimauchi T., Funakoshi A., Ito N., Fukamizu H., et al. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci 2013, 69:140-147.
37. Shin B.S., Furuhashi T., Nakamura M., Torii K., Morita A. Impaired inhibitory function of circulating CD4+CD25+ regulatory T cells in alopecia areata. J Dermatol Sci 2013, 70:141-143.
38. Ferran M., Calvet J., Almirall M., Pujol R.M., Maymó J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: report of five cases and review of the literature. J Eur Acad Dermatol Venereol 2011, 25:479-484.
39. Ito T., Ito N., Saatoff M., Hashizume H., Fukamizu H., Nickoloff B.J., et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008, 128:1196-1206.
40. Ito T. Hair follicle is a target of stress hormone and autoimmune reactions. J Dermatol Sci 2010, 60:67-73.
41. Pan F., Yu H., Dang E.V., Barbi J., Pan X., Grosso J.F., et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 2009, 325:1142-1146.
42. Lien E., Ingalls R.R. Toll-like receptors. Crit Care Med 2002, 30:S1-S11.
43. Ito T., Bertolini M., Funakoshi A., Ito N., Takayama T., Biro T., et al. Birth, life, and death of the MAGE3 hypothesis of alopecia areata pathobiology. J Dermatol Sci 2013, 72:327-330.
44. Chu S.Y., Chen Y.J., Tseng W.C., Lin M.W., Chen T.J., Hwang C.Y., et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol 2011, 65:949-956.
45. Huang K.P., Mullangi S., Guo Y., Qureshi A.A. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol 2013, 149:789-794.
46. Karopka T., Fluck J., Mevissen H.T., Glass A. The autoimmune disease database: a dynamically compiled literature-derived database. BMC Bioinform 2006, 7:325.
47. Xing L., Dai Z., Jabbari A., Cerise J.E., Higgins C.A., Gong W., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014, 20:1043-1049.
48. Craiglow B.G., King B.A. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 2014, 134:2988-2990.
49. Paus R., Arck P. Neuroendocrine perspectives in alopecia areata: does stress play a role?. J Invest Dermatol 2009, 129:1324-1326.
50. Paus R., Langan E.A., Vidali S., Ramot Y., Andersen B. Neuroendocrinology of the hair follicle: principles and clinical perspectives. Trends Mol Med 2014, 20:559-570.
51. Zhang X., Yu M., Yu W., Weinberg J., Shapiro J., McElwee K.J. Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3H/HeJ mouse model. J Invest Dermatol 2009, 129:1527-1538.
52. Ramot Y., Paus R. Harnessing neuroendocrine controls of keratin expression: a new therapeutic strategy for skin diseases?. Bioessays 2014, 36:672-686.
53. Duvic M., Christiano A.M., Hordinsky M.K., Norris D.A., Price V.H., Amos C.I. The national alopecia areata registry-update. J Invest Dermatol Symp Proc 2013, 16:S53.